MedTrace Logo

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance

NCT04429152 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-06-07

No results posted yet for this study

Summary

This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological failure on first-line Efavirenz-based antiretroviral therapy with non-nucleoside reverse transcriptase inhibitor resistance

Conditions

Interventions

DRUG

Doravirine/Lamivudine/Tenofovir

DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination

Sponsors & Collaborators

  • Professor Francois Venter

    lead OTHER

Principal Investigators

  • Simiso Sokhela, MBBCh · Ezintsha, a subdivision of Wits Reproductive Health and HIV Institute (Wits RHI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-09
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429152 on ClinicalTrials.gov